Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for chronic lymphocytic leukaemia:
- Zanubrutinib for treating chronic lymphocytic leukaemia (2023) NICE technology appraisal guidance 931
- Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (2023) NICE technology appraisal guidance 891
- Acalabrutinib for treating chronic lymphocytic leukaemia (2021) NICE technology appraisal guidance 689
- Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (2020) NICE technology appraisal guidance 663
- Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (2019) NICE technology appraisal guidance 561
- Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (2017) NICE technology appraisal guidance 429
This page was last updated: